Speaker illustration

Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

Member of:

European Society of Cardiology

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

Event: ESC Congress 2022

Topic: Thrombosis, Platelets, and Coagulation

Session: What’s new on lipids and diabetes in acute coronary syndrome

Thumbnail

This platform is supported by

logo Novo Nordisk